StockData
Palvella Therapeutics, Inc. logo

Palvella Therapeutics, Inc. (PVLA) stock

PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$144.35−0.25 (-0.17%)

Close on Nov 17, 2026Market cap $2.08BP/E –Yield –

Earnings

Palvella Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 30, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$1.70
-$1.03 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Palvella Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 30, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026before the open––-$1.70Release
Q2 FY2026ended Jun 30, 2026Aug 4, 2026before the open––-$1.52Release
Q1 FY2026ended Mar 31, 2026May 7, 2026before the open––-$1.20Release
Q4 FY2025ended Dec 31, 2025Mar 31, 2026before the open–––Release
Q3 FY2025ended Sep 30, 2025Nov 10, 2025after the close––-$1.03Release
Q2 FY2025ended Jun 30, 2025Aug 14, 2025before the open––-$0.86Release
Q1 FY2025ended Mar 31, 2025May 15, 2025before the open––-$0.74Release
Q4 FY2024ended Dec 31, 2024Mar 31, 2025before the open–––Release
Q4 FY2023ended Dec 31, 2023Mar 27, 2024before the open–––Release
Q2 FY2023ended Jun 30, 2023Jul 18, 2023before the open–––Release
Q1 FY2023ended Mar 31, 2023May 10, 2023before the open$1.94M-82.4%-$0.18Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Palvella Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Palvella Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Palvella Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. News
  4. Results
  5. Results
  6. News
  7. News
  8. News
  9. Results
  10. Results
  11. News
  12. Results
  13. Results
  14. Update
  15. News

See a number that looks wrong?